
Yoshito Komatsu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/214451/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study. Advances in Therapy, 2022, 39, 296-313.	1.3	13
2	A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain. Anticancer Research, 2022, 42, 343-348.	0.5	0
3	Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). Oncologist, 2022, 27, 340-e374.	1.9	2
4	Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502â€A1. Cancer Science, 2022, 113, 1018-1027.	1.7	4
5	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer. Clinical Cancer Research, 2022, 28, 1136-1146.	3.2	62
6	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress) Journal of Clinical Oncology, 2022, 40, TPS215-TPS215.	0.8	3
7	HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy for gastrointestinal cancer Journal of Clinical Oncology, 2022, 40, 649-649.	0.8	0
8	Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program Journal of Clinical Oncology, 2022, 40, 199-199.	0.8	2
9	The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. Cancer Medicine, 2022, , .	1.3	2
10	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO Precision Oncology, 2022, 6, e2100383.	1.5	8
11	Characteristics of anal canal cancer in Japan. Cancer Medicine, 2022, 11, 2735-2743.	1.3	9
12	Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer. Supportive Care in Cancer, 2022, , 1.	1.0	2
13	Rapid Screening Using Pathomorphologic Interpretation to Detect <i>BRAF</i> V600E Mutation and Microsatellite Instability in Colorectal Cancer. Clinical Cancer Research, 2022, 28, 2623-2632.	3.2	4
14	A Survey Using a Terminal Care Attitude Scale Intended for Oncologists and Palliative Care Staff. Palliative Care Research, 2022, 17, 51-58.	0.0	0
15	Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603. Oncologist, 2022, 27, e642-e649.	1.9	8
16	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncology, 2022, 18, 2351-2360.	1.1	22
17	Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. BMJ Open, 2022, 12, e048833.	0.8	1
18	Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma Journal of Clinical Oncology, 2022, 40, 3571-3571	0.8	0

#	Article	IF	CITATIONS
19	An investigator-initiated phase II trial of a PARP inhibitor niraparib monotherapy for patients with pre-treated, <i>BRCA</i> -mutated, unresectable/recurrent biliary tract, pancreatic, and other gastrointestinal cancers (NIR-B trial) Journal of Clinical Oncology, 2022, 40, TPS4174-TPS4174.	0.8	0
20	Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> fusions/rearrangements Journal of Clinical Oncology, 2022, 40, 4009-4009.	0.8	33
21	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration Journal of Clinical Oncology, 2022, 40, 4086-4086.	0.8	Ο
22	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial) Journal of Clinical Oncology, 2022, 40, 4006-4006.	0.8	44
23	Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial Journal of Clinical Oncology, 2022, 40, LBA1-LBA1.	0.8	52
24	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 113-120.e1.	1.0	22
25	Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Supportive Care in Cancer, 2021, 29, 3277-3285.	1.0	8
26	Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Gastric Cancer, 2021, 24, 467-476.	2.7	4
27	Hypertriglyceridemia induced by S-1: A novel case report and review of the literature. Journal of Oncology Pharmacy Practice, 2021, 27, 1020-1025.	0.5	7
28	Translational research of VOLTAGE-A: Efficacy predictors of preoperative chemoradiotherapy and consolidation nivolumab in patients with both microsatellite stable and microsatellite instability-high locally advanced rectal cancer Journal of Clinical Oncology, 2021, 39, 100-100.	0.8	6
29	Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study Journal of Clinical Oncology, 2021, 39, 57-57.	0.8	Ο
30	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer Journal of Clinical Oncology, 2021, 39, 85-85.	0.8	6
31	Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen Journal of Clinical Oncology, 2021, 39, 106-106.	0.8	3
32	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT,) Tj ETQq0 0 () rg ₿.₸ /Ove	erlo ici k 10 Tf 50
33	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clinical Cancer Research, 2021, 27, 2515-2522.	3.2	39
34	A case of immune checkpoint <scp>inhibitorâ€associated</scp> gastroenteritis detected by ultrasonography. Journal of Clinical Ultrasound, 2021, 49, 605-609.	0.4	6
35	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatinâ€based or irinotecanâ€based therapy for colorectal cancer. Cancer Science, 2021, 112, 1567-1578.	1.7	5
36	Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. Japanese Journal of Clinical Oncology, 2021, 51, 879-885.	0.6	0

#	Article	IF	CITATIONS
37	Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. Japanese Journal of Clinical Oncology, 2021, 51, 753-761.	0.6	10
38	A randomized, doubleâ€blind, phase II study of oral histone deacetylase inhibitor resminostat plus Sâ€1 versus placebo plus Sâ€1 in biliary tract cancers previously treated with gemcitabine plus platinumâ€based chemotherapy. Cancer Medicine, 2021, 10, 2088-2099.	1.3	1
39	Evaluation of Chemotherapy Regimen Management Practice by Oncology-Specialized and Non-specialized Pharmacists Collaboration. Biological and Pharmaceutical Bulletin, 2021, 44, 293-297.	0.6	2
40	Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report. Case Reports in Oncology, 2021, 14, 207-211.	0.3	2
41	Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study. Biological and Pharmaceutical Bulletin, 2021, 44, 474-477.	0.6	3
42	Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. International Journal of Clinical Oncology, 2021, 26, 1238-1247.	1.0	2
43	Discovery of a potential predictive marker for eribulin treatment and novel target genes in BRAF V600E mutant metastatic colorectal cancer using an Al-driven RNA-seq analysis platform: Translational research of the BRAVERY study (EPOC1701) Journal of Clinical Oncology, 2021, 39, e15532-e15532.	0.8	0
44	Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903) Journal of Clinical Oncology, 2021, 39, TPS4152-TPS4152.	0.8	0
45	Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG) Journal of Clinical Oncology, 2021, 39, 11524-11524.	0.8	16
46	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a firstâ€line treatment for metastatic colorectal cancer: Safety leadâ€in results from the QUATTRO-II study. Investigational New Drugs, 2021, 39, 1649-1655.	1.2	3
47	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	5.1	234
48	A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Oncologist, 2021, 26, e1675-e1682.	1.9	3
49	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Research, 2021, 81, CT010-CT010.	0.4	28
50	The Prognostic Impact of <i>KRAS</i> G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. Oncologist, 2021, 26, 845-853.	1.9	26
51	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. Clinical Cancer Research, 2021, 27, 5619-5627.	3.2	27
52	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. European Journal of Cancer, 2021, 154, 296-306.	1.3	5
53	Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 2025-2028.	1.0	3
54	Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. Clinical Drug Investigation, 2021, 41, 53-64.	1.1	1

#	Article	IF	CITATIONS
55	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nature Medicine, 2021, 27, 1899-1903.	15.2	110
56	Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation. Biological and Pharmaceutical Bulletin, 2021, 44, 1819-1823.	0.6	3
57	Immune Checkpoint Inhibitor-Induced Colitis Successfully Followed up by Ultrasonography. SN Comprehensive Clinical Medicine, 2020, 2, 215-221.	0.3	3
58	Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. International Journal of Clinical Oncology, 2020, 25, 614-621.	1.0	13
59	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemotherapy and Pharmacology, 2020, 85, 217-223.	1.1	13
60	Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Medicine (United States), 2020, 99, e22250.	0.4	14
61	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature Medicine, 2020, 26, 1859-1864.	15.2	209
62	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894.	3.2	44
63	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist, 2020, 25, e1855-e1863.	1.9	28
64	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study. International Journal of Clinical Oncology, 2020, 25, 1800-1806.	1.0	1
65	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer, 2020, 20, 687.	1.1	9
66	nalâ€ŀRI+5â€FU/LV versus 5â€FU/LV in postâ€gemcitabine metastatic pancreatic cancer: Randomized phase 2 tria in Japanese patients. Cancer Medicine, 2020, 9, 9396-9408.	 1.3	26
67	Clinical impact of a cancer genomic profiling test using an inâ€house comprehensive targeted sequencing system. Cancer Science, 2020, 111, 3926-3937.	1.7	20
68	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. European Journal of Cancer, 2020, 129, 97-106.	1.3	48
69	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapyâ€associated hepatitis in Japan. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1782-1788.	1.4	22
70	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). Oncology, 2020, 98, 719-726.	0.9	0
71	BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open, 2020, 5, e000624.	2.0	15
72	Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer Journal of Clinical Oncology, 2020, 38, 4073-4073.	0.8	3

#	Article	IF	CITATIONS
73	Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer Journal of Clinical Oncology, 2020, 38, 4100-4100.	0.8	40
74	A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial) Journal of Clinical Oncology, 2020, 38, TPS3650-TPS3650.	0.8	5
75	Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial Journal of Clinical Oncology, 2020, 38, TPS4654-TPS4654.	0.8	10
76	Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503) Journal of Clinical Oncology, 2020, 38, 107-107.	0.8	3
77	Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2020, 38, 169-169.	0.8	4
78	Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis Journal of Clinical Oncology, 2020, 38, 5-5.	0.8	3
79	Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression Journal of Clinical Oncology, 2020, 38, 538-538.	0.8	3
80	Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. Global Health & Medicine, 2020, 2, 240-246.	0.6	4
81	Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2020, 38, 823-823.	0.8	4
82	S-1+oxaliplatin with pembrolizumab for advanced gastric cancer: The cohort 1 in a phase IIb KEYNOTE-659 study Journal of Clinical Oncology, 2020, 38, 382-382.	0.8	0
83	HCCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy—Updated analysis of antitumor efficacy Journal of Clinical Oncology, 2020, 38, 108-108.	0.8	1
84	Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis Journal of Clinical Oncology, 2020, 38, 3516-3516.	0.8	2
85	Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis Journal of Clinical Oncology, 2020, 38, 4071-4071.	0.8	Ο
86	HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment Journal of Clinical Oncology, 2020, 38, TPS4668-TPS4668.	0.8	0
87	Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors. Biological and Pharmaceutical Bulletin, 2020, 43, 1969-1974.	0.6	7
88	The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study Journal of Clinical Oncology, 2020, 38, 296-296.	0.8	0
89	A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of albumin-bilirubin (ALBI) grade Journal of Clinical Oncology, 2020, 38, 415-415.	0.8	6
90	VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy Journal of Clinical Oncology, 2020, 38, 100-100.	0.8	1

#	Article	IF	CITATIONS
91	Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment Journal of Clinical Oncology, 2020, 38, TPS267-TPS267.	0.8	0
92	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. , 2019, 7, 219.		19
93	Exploration of potential prognostic biomarkers in aflibercept plus <scp>FOLFIRI</scp> in Japanese patients with metastatic colorectal cancer. Cancer Science, 2019, 110, 3565-3572.	1.7	11
94	Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinibÂand regorafenib: a phase II, single-arm trial. European Journal of Cancer, 2019, 121, 29-39.	1.3	38
95	One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist, 2019, 24, 1593-1600.	1.9	21
96	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 982-986.	2.9	64
97	Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer, 2019, 19, 255.	1.1	16
98	Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a secondâ€line treatment for Japanese patients with metastatic colorectal cancer. Cancer Science, 2019, 110, 1032-1043.	1.7	30
99	Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open, 2019, 4, e000590.	2.0	1
100	Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. Oncologist, 2019, 24, e450-e457.	1.9	28
101	Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ESMO Open, 2019, 4, e000584.	2.0	7
102	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer, 2019, 22, 344-354.	2.7	60
103	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer, 2019, 22, 817-827.	2.7	42
104	Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer Journal of Clinical Oncology, 2019, 37, 3606-3606.	0.8	12
105	Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer Journal of Clinical Oncology, 2019, 37, e15106-e15106.	0.8	1
106	TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA Journal of Clinical Oncology, 2019, 37, TPS3156-TPS3156.	0.8	2
107	Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study Journal of Clinical Oncology, 2019, 37, 624-624.	0.8	1
108	Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer Journal of Clinical Oncology, 2019, 37, 84-84.	0.8	1

#	Article	IF	CITATIONS
109	Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors Journal of Clinical Oncology, 2019, 37, 99-99.	0.8	2
110	bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB) Journal of Clinical Oncology, 2019, 37, TPS179-TPS179.	0.8	2
111	A retrospective analysis of neoadjuvant chemotherapy followed by surgery or definitive chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma Journal of Clinical Oncology, 2019, 37, 115-115.	0.8	0
112	Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer Journal of Clinical Oncology, 2019, 37, 359-359.	0.8	0
113	HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer Journal of Clinical Oncology, 2019, 37, TPS183-TPS183.	0.8	0
114	Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA Journal of Clinical Oncology, 2019, 37, 3528-3528.	0.8	3
115	Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer Journal of Clinical Oncology, 2019, 37, 3560-3560.	0.8	1
116	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology, 2018, 94, 289-296.	0.9	5
117	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. European Journal of Cancer, 2018, 91, 86-91.	1.3	48
118	Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist, 2018, 23, 7-15.	1.9	82
119	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. Gastric Cancer, 2018, 21, 429-438.	2.7	26
120	The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring. Internal Medicine, 2018, 57, 2527-2531.	0.3	1
121	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 198-205.	1.0	57
122	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology, 2018, 18, 647-654.	0.5	35
123	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. Clinical Colorectal Cancer, 2018, 17, e719-e732.	1.0	10
124	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e687-e697.	1.0	15
125	Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN Journal of Clinical Oncology, 2018, 36, 12094-12094.	0.8	9
126	REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis Journal of Clinical Oncology, 2018, 36, 3510-3510.	0.8	5

#	Article	IF	CITATIONS
127	APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, 3523-3523.	0.8	7
128	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503 Journal of Clinical Oncology, 2018, 36, 3530-3530.	0.8	10
129	Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan Journal of Clinical Oncology, 2018, 36, 557-557.	0.8	9
130	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of tumor location Journal of Clinical Oncology, 2018, 36, 802-802.	0.8	1
131	VOLTACE: Multicenter phase 1b/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer Journal of Clinical Oncology, 2018, 36, TPS878-TPS878.	0.8	3
132	A Case Report of Successful Conversion Therapy with XELOX + Bevacizumab in a Patient with AFP-producing Colon Cancer and Synchronous Liver Metastases. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2018, 43, 845-854.	0.0	0
133	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib Journal of Clinical Oncology, 2018, 36, 832-832.	0.8	Ο
134	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503 Journal of Clinical Oncology, 2018, 36, 760-760.	0.8	0
135	Safety of administration of bevacizumab within a week from placement of a totally implantable central venous port system Journal of Clinical Oncology, 2018, 36, 589-589.	0.8	Ο
136	Clinical implementation of a comprehensive targeted amplicon sequencing system for the patients with gastrointestinal cancer as a real world evidence in Japan Journal of Clinical Oncology, 2018, 36, 329-329.	0.8	1
137	Predictive value of tumor growth rate during previous treatment for tumor response to regorafenib (REGO) and trifluridine/tipiracil (TFTD) in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, 766-766.	0.8	Ο
138	Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, 642-642.	0.8	9
139	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402 Journal of Clinical Oncology, 2018, 36, 10094-10094.	0.8	Ο
140	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naà ve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic ColorectalÂCancer. Clinical Colorectal Cancer, 2017, 16, 158-163.	1.0	13
141	A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). Oncologist, 2017, 22, 592-600.	1.9	30
142	Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer. Tumor Biology, 2017, 39, 101042831769454.	0.8	8
143	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1197-1207.	1.1	27
144	S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open, 2017, 2, e000135.	2.0	17

#	Article	IF	CITATIONS
145	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open, 2017, 2, e000261.	2.0	22
146	A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. Japanese Journal of Clinical Oncology, 2017, 47, 1002-1009.	0.6	3
147	Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer, 2017, 17, 837.	1.1	5
148	Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2017, 8, 566-571.	0.6	67
149	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503 Journal of Clinical Oncology, 2017, 35, TPS3623-TPS3623.	0.8	2
150	Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205 Journal of Clinical Oncology, 2017, 35, 151-151.	0.8	2
151	Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo Journal of Clinical Oncology, 2017, 35, 529-529.	0.8	2
152	Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2017, 35, 721-721.	0.8	10
153	A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study Journal of Clinical Oncology, 2017, 35, 722-722.	0.8	1
154	A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results Journal of Clinical Oncology, 2017, 35, 770-770.	0.8	2
155	Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2017, 35, 775-775.	0.8	9
156	Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer—HGCSG1401 Journal of Clinical Oncology, 2017, 35, 778-778.	0.8	6
157	Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) + FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2017, 35, 799-799.	0.8	3
158	A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602 Journal of Clinical Oncology, 2017, 35, TPS809-TPS809.	0.8	0
159	North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HCCSG1003) Journal of Clinical Oncology, 2017, 35, 807-807.	0.8	0
160	A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2017, 35, 707-707.	0.8	2
161	Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting Journal of Clinical Oncology, 2017, 35, e21688-e21688.	0.8	0
162	Clinical implementation of a comprehensive targeted amplicon sequencing system for cancer in Japan Journal of Clinical Oncology, 2017, 35, e13115-e13115.	0.8	0

#	Article	IF	CITATIONS
163	Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience. Journal of Gastric Cancer, 2016, 16, 177.	0.9	2
164	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist, 2016, 21, 1483-1491.	1.9	64
165	Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. Journal of Infection and Chemotherapy, 2016, 22, 826-829.	0.8	2
166	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer, 2016, 19, 927-938.	2.7	67
167	A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402) Journal of Clinical Oncology, 2016, 34, 10127-10127.	0.8	3
168	Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial Journal of Clinical Oncology, 2016, 34, 3547-3547.	0.8	3
169	Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, 3556-3556.	0.8	5
170	Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030) Journal of Clinical Oncology, 2016, 34, 3557-3557.	0.8	5
171	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, TPS3625-TPS3625.	0.8	1
172	TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial Journal of Clinical Oncology, 2016, 34, 634-634.	0.8	9
173	TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial Journal of Clinical Oncology, 2016, 34, 638-638.	0.8	3
174	Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups Journal of Clinical Oncology, 2016, 34, 646-646.	0.8	7
175	Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS) Journal of Clinical Oncology, 2016, 34, 680-680.	0.8	4
176	Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan Journal of Clinical Oncology, 2016, 34, 96-96.	0.8	1
177	PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, TPS776-TPS776.	0.8	3
178	A case of hepatic lymphoma showing a mixed pattern on contrast-enhanced ultrasonography. Choonpa Igaku, 2016, 43, 115-122.	0.0	1
179	Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802)—Sub-group analysis by KRAS Exon2 status Journal of Clinical Oncology, 2016, 34, 522-522.	0.8	0
180	Prospective observational study for the impact of short-term periodic intravenous steroid premedication for gastrointestinal cancer chemotherapy on bone metabolism Journal of Clinical Oncology, 2016, 34, 523-523.	0.8	1

#	Article	IF	CITATIONS
181	Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802—Analysis of early tumor shrinkage (ETS) Journal of Clinical Oncology, 2016, 34, 753-753.	0.8	0
182	Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502) Journal of Clinical Oncology, 2016, 34, TPS177-TPS177.	0.8	0
183	Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index Journal of Clinical Oncology, 2016, 34, 743-743.	0.8	0
184	Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment Journal of Clinical Oncology, 2016, 34, 771-771.	0.8	0
185	Update analysis: Prospective observational study for the impact of short-term periodic steroid premedication for cancer chemotherapy on bone metabolism—ESPRESSO-01 study Journal of Clinical Oncology, 2016, 34, e18145-e18145.	0.8	0
186	Openâ€label, randomized, comparative, phase <scp>III</scp> study on effects of reducing steroid use in combination with Palonosetron. Cancer Science, 2015, 106, 891-895.	1.7	39
187	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer, 2015, 15, 626.	1.1	13
188	Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Japanese Journal of Clinical Oncology, 2015, 45, 1016-1022.	0.6	13
189	Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. Japanese Journal of Clinical Oncology, 2015, 45, 43-48.	0.6	10
190	Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. International Journal of Clinical Oncology, 2015, 20, 905-912.	1.0	27
191	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer, 2015, 18, 824-832.	2.7	91
192	RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis Journal of Clinical	0.8	5
193	Oncology, 2015, 33, 11-11. Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802 Journal of Clinical Oncology, 2015, 33, 749-749.	0.8	34
194	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status Journal of Clinical Oncology, 2015, 33, 782-782.	0.8	0
195	Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSC0901 Journal of Clinical Oncology, 2015, 33, 781-781.	0.8	Ο
196	Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A) Journal of Clinical Oncology, 2015, 33, 127-127.	0.8	0
197	Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment Journal of Clinical Oncology, 2015, 33, 746-746.	0.8	1
198	Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802 Journal of Clinical Oncology, 2015, 33, 743-743.	0.8	0

#	Article	IF	CITATIONS
199	Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003): Detailed analysis of peripheral sensory neuropathy Journal of Clinical Oncology, 2015, 33, 701-701.	0.8	15
200	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV Journal of Clinical Oncology, 2015, 33, 527-527.	0.8	0
201	ReGISTry Study of High Risk GIST Patients After Complete Resection:The adjuvant therapy and pathological diagnosis in Japan Journal of Clinical Oncology, 2015, 33, 10533-10533.	0.8	0
202	Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. Gastroenterology Research and Practice, 2014, 2014, 1-6.	0.7	9
203	Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Investigational New Drugs, 2014, 32, 473-480.	1.2	25
204	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1224-1235.	5.1	1,932
205	Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/ <i>l</i> -LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2014, 32, 3586-3586.	0.8	2
206	RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapyâ€"Efficacy analysis in Japanese and Western patients	0.8	13
207	Journal of Clinical Oncology, 2014, 32, 4005-4005. Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma Journal of Clinical Oncology, 2014, 32, 4051-4051.	0.8	2
208	Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer Journal of Clinical Oncology, 2014, 32, 163-163.	0.8	1
209	Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901 Journal of Clinical Oncology, 2014, 32, 634-634.	0.8	0
210	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with) Tj ETQq0 () 0og8T /C	veolock 10 Tf
211	Comparison of adding cetuximab (Cmab) or panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002 Journal of Clinical Oncology, 2014, 32, 598-598.	0.8	0
212	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies Journal of Clinical Oncology, 2014, 32, 603-603.	0.8	0
213	Updated analysis of HERBIS-1: A phase II study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer Journal of Clinical Oncology, 2014, 32, 98-98.	0.8	0
214	Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002 Journal of Clinical Oncology, 2014, 32, 663-663.	0.8	4
215	Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: HGCSG0704 Journal of Clinical Oncology, 2014, 32, 624-624.	0.8	0
216	Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report Journal of Clinical Oncology, 2014, 32, 113-113.	0.8	0

#	Article	IF	CITATIONS
217	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGSG1001 (Japanese Skin Toxicity Evaluation Protocol with) Tj ETQq1	1 0.784314 0.8	rgBT /Overloo
218	32, 3587-3587. A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study Journal of Clinical Oncology, 2013, 31, 3519-3519.	0.8	2
219	Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer Journal of Clinical Oncology, 2013, 31, 263-263.	0.8	12
220	A phase II study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1) Journal of Clinical Oncology, 2013, 31, 70-70.	0.8	5
221	Retrospective cohort study on the safety and efficacy of panitumumab (Pmab) for patients with metastatic colorectal cancer (mCRC): The HGCSG1002 study—Analysis of clinical early predictor for the efficacy Journal of Clinical Oncology, 2013, 31, 593-593.	0.8	0
222	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial Journal of Clinical Oncology, 2013, 31, 460-460.	0.8	0
223	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial—Comparison of the efficacy of KRAS status Journal of Clinical Oncology, 2013, 31, 536-536.	0.8	0
224	An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 split cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702—Safety analysis Journal of Clinical Oncology, 2013, 31, 121-121.	0.8	0
225	Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study—Analysis of adverse events Journal of Clinical Oncology, 2013, 31, 554-554.	0.8	0
226	Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study—Analysis of after cetuximab refractory Journal of Clinical Oncology, 2013, 31, 541-541.	0.8	0
227	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies Journal of Clinical Oncology, 2013, 31, e14604-e14604.	0.8	0
228	A phase II study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1) Journal of Clinical Oncology, 2013, 31, 4072-4072.	0.8	0
229	Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study Journal of Clinical Oncology, 2013, 31, 3638-3638.	0.8	1
230	Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncológica, 2012, 51, 867-872.	0.8	20
231	Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegaful, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer Journal of Clinical Oncology, 2012, 30, 141-141.	0.8	0
232	Safety report of a phase II trial of irinotecan plus S-1 (IRIS) with cetuximab in patients with KRAS wild type of metastatic colorectal cancer: HGCSG0902 Journal of Clinical Oncology, 2012, 30, e14062-e14062.	0.8	0
233	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial Journal of Clinical Oncology, 2012, 30, 3593-3593.	0.8	0
234	Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). Anti-Cancer Drugs, 2011, 22, 576-583.	0.7	16

#	Article	IF	CITATIONS
235	Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302). Oncology, 2011, 80, 70-75.	0.9	22